InnovAge Holding Corp is expected to report consensus revenue of $228.4 million and EPS of $0.11, with the current stock price of $7.45 trading below the average analyst price target of $8.50. The primary focus for investors this quarter is the Total Census growth, which tracks the number of participants enrolled in the company’s PACE programs.
Investors are looking for evidence that the company can sustain enrollment momentum following its successful emergence from previous regulatory sanctions and center-level operational improvements. Analysts are particularly attentive to whether de novo centers are scaling efficiently to support long-term profitability targets.